Filing Details

Accession Number:
0001209191-17-037970
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-05 19:25:00
Reporting Period:
2017-06-01
Filing Date:
2017-06-05
Accepted Time:
2017-06-05 19:25:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1435049 Aduro Biotech Inc. ADRO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1635590 W. Thomas Dubensky C/O Aduro Biotech, Inc.
740 Heinz Avenue
Berkeley CA 94710
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-01 77,971 $0.52 117,871 No 4 M Direct
Common Stock Disposition 2017-06-01 77,971 $10.00 39,900 No 4 S Direct
Common Stock Acquisiton 2017-06-02 48,753 $0.52 88,653 No 4 M Direct
Common Stock Disposition 2017-06-02 48,753 $10.10 39,900 No 4 S Direct
Common Stock Acquisiton 2017-06-05 17,577 $0.52 57,477 No 4 M Direct
Common Stock Disposition 2017-06-05 17,577 $9.99 39,900 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2017-06-01 77,971 $0.00 77,971 $0.52
Common Stock Employee Stock Option (right to buy) Disposition 2017-06-02 48,753 $0.00 48,753 $0.52
Common Stock Employee Stock Option (right to buy) Disposition 2017-06-05 17,577 $0.00 17,577 $0.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
129,901 2021-10-23 No 4 M Direct
81,148 2021-10-23 No 4 M Direct
63,571 2021-10-23 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The shares subject to the Option were fully vested as of September 1, 2015.